CY1107470T1 - Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι - Google Patents

Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι

Info

Publication number
CY1107470T1
CY1107470T1 CY20061100939T CY061100939T CY1107470T1 CY 1107470 T1 CY1107470 T1 CY 1107470T1 CY 20061100939 T CY20061100939 T CY 20061100939T CY 061100939 T CY061100939 T CY 061100939T CY 1107470 T1 CY1107470 T1 CY 1107470T1
Authority
CY
Cyprus
Prior art keywords
proteins
leptin
compositions
glycosylated
methods
Prior art date
Application number
CY20061100939T
Other languages
Greek (el)
English (en)
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1107470T1 publication Critical patent/CY1107470T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20061100939T 1999-02-12 2006-07-07 Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι CY1107470T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12
EP00911784A EP1151102B1 (en) 1999-02-12 2000-02-11 Glycosylated leptin compositions and related methods

Publications (1)

Publication Number Publication Date
CY1107470T1 true CY1107470T1 (el) 2012-12-19

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100939T CY1107470T1 (el) 1999-02-12 2006-07-07 Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι

Country Status (11)

Country Link
EP (1) EP1151102B1 (enExample)
JP (1) JP4841037B2 (enExample)
AT (1) ATE323766T1 (enExample)
AU (1) AU781460B2 (enExample)
CA (1) CA2359840C (enExample)
CY (1) CY1107470T1 (enExample)
DE (1) DE60027409T2 (enExample)
DK (1) DK1151102T3 (enExample)
ES (1) ES2257287T3 (enExample)
PT (1) PT1151102E (enExample)
WO (1) WO2000047741A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2003020303A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
EP1444516B1 (en) * 2001-10-22 2010-07-21 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
US20040248262A1 (en) 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
AU2004276522B2 (en) 2003-09-26 2010-12-02 Merck Serono Sa Leader sequences for use in production of proteins
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
MX351128B (es) 2010-09-28 2017-10-03 Aegerion Pharmaceuticals Inc Polipeptidos manipulados que tienen duracion de accion incrementada.
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US9968575B2 (en) 2012-09-27 2018-05-15 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
NZ527007A (en) * 1995-11-22 2005-01-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
EP0877627A1 (en) * 1996-01-25 1998-11-18 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU4160597A (en) * 1996-08-23 1998-03-06 Eli Lilly And Company Protein formulations
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
WO2000009165A1 (en) * 1998-08-10 2000-02-24 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
AU781460B2 (en) 2005-05-26
CA2359840C (en) 2012-10-23
ES2257287T3 (es) 2006-08-01
JP4841037B2 (ja) 2011-12-21
DE60027409T2 (de) 2007-04-12
PT1151102E (pt) 2006-07-31
JP2002536018A (ja) 2002-10-29
ATE323766T1 (de) 2006-05-15
EP1151102A1 (en) 2001-11-07
CA2359840A1 (en) 2000-08-17
AU3362300A (en) 2000-08-29
WO2000047741A1 (en) 2000-08-17
EP1151102B1 (en) 2006-04-19
DE60027409D1 (de) 2006-05-24
DK1151102T3 (da) 2006-05-29

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
Lawler et al. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
DE60307701D1 (de) Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
WO2003059934A3 (en) Albumin fusion proteins
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
WO2002060955A3 (en) Modified antibodies and methods of use
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
NO20080045L (no) Glykosylert UL-7, fremstilling og anvendelse av samme
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
CA2031430A1 (en) Process for refolding recombinantly produced tgf-.beta.-like proteins
BR0007840A (pt) Proteìnas de fusão her-2/neu
EP0797999A3 (en) Formulations of obesity protein
FI20075338A7 (fi) gp350/220:n ei silmukoivia muutoksia
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
ES2017122A6 (es) Procedimiento de preparacion de proteina de ligado de heparina.
DE60129528D1 (de) Impfstoffe, die hybride Polypeptide mit mindestens zwei verschiedene Allergenen enthalten
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
CA2002833A1 (en) Interferon-gamma binding proteins
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen